Rivaroxaban
Atrial Flutter
University of EdinburghSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Atrial Flutter cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dabigatran University of Edinburgh | Phase 4 | BBB |
Edoxaban St. Antonius Hospital | Phase 4 | BBB |
WARFARIN University of Edinburgh | Phase 3 | BB |
Apixaban University of Edinburgh | Phase 3 | BB |
3-(.ALPHA.-ACETONYL-P-NITROBENZYL)-4-HYDROXYCOUMARIN University of Edinburgh | Phase 3 | BB |
Phenindione University of Edinburgh | Phase 3 | BB |
Same molecule, other indications
Rivaroxaban is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →